

PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DOUGLAS P. CERRETTI

Appln. No. 08/538,709

Group Art Unit: 1647

Filed: October 3, 1995

Examiner: Draper, G.

For: DNA ENCODING CYTOKINE DESIGNATED

LERK-6

Corrected

DECLARATION UNDER 37 C.F.R. § 1.131

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

I, DOUGLAS P. CERRETTI do hereby declare and state:

I am the inventor of the invention disclosed and claimed in the above-mentioned application.

I am familiar with U.S. Patent 5,795,734, issued to Flanagan on August 18, 1998 (hereinafter the "Flanagan Patent"), from U.S. Patent Application Serial No. 08/455,001, filed May 31, 1995 (hereinafter the "Flanagan Application"), which I understand is a Continuation-In-Part of Serial No. 08/393,461, filed February 27, 1995 (hereinafter the "Flanagan Parent Application"), which is a Continuation-In-Part of Serial No. 08/308,814, filed September 19, 1994 (hereinafter the "Flanagan Grandparent Application").

The Flanagan Patent discloses DNA encoding Elf-1, a mouse polypeptide which is now known in the art as mouse LERK-6.

In order to demonstrate and establish, *inter alia*, that I conceived and reduced to practice a DNA molecule encoding a polypeptide having mouse LERK-6 sequences in the United States by at least September 15, 1994, i.e., prior to the

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

September 19, 1994, filing date of the Flanagan Grandparent Application, copies of the following laboratory notebook pages and related materials, identified in detail below, are provided herewith in Appendices A-G.

I declare and state that although all of the dates from the laboratory notebook pages and related materials have been removed, all of the dates are prior to at least September 15, 1994.

Appendix A contains pages from Nicole Nelson's Laboratory Notebook No. 4266 (Bates Nos. 0001-0007). At the time, Nicole Nelson was a Research Assistant who worked under my direction and supervision at Immunex Corporation.

Appendix B contains a copy of U.S. Patent 5,516,658 (Bates Nos. 0008-0026).

Appendix C contains oligonucleotide request forms prepared by Carl Kozlosky (Bates Nos. 0027-0030). At the time, Carl Kozlosky was a Research Associate who worked under my direction and supervision at Immunex Corporation.

Appendix D contains pages from Carl Kozlosky's Laboratory Notebook No. 3388 (Bates Nos. 0031-0037).

Appendix E contains various computer printouts of LERK sequences that I personally generated (Bates Nos. 0038-0049).

Appendix F contains the minutes of an internal HEK/ELK meeting at Immunex Corporation that was chaired by Barry Davison in my absence (Bates Nos. 0050-0051). Barry Davison, who prepared the minutes, was the Director of the Transgenics Department at Immunex Corporation at the time.

Appendix G contains a copy of American Type Culture Collection Form BP4/9 for ATCC deposit No. 75829 (Bates No. 0052).

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

Prior to September 15, 1994, and as described in Example 1 of the present application, a DNA molecule encoding mouse LERK-6 was isolated under my direction and supervision. The specific experiments detailed below were carried out at my behest and command and under my direction and supervision by scientists at Immunex Corporation.

More specifically, prior to September 15, 1994, and as described at page 23, lines 5-7 of the present application, a commercially available 11.5 day murine embryonic cDNA library was obtained by Nicole Nelson from Clonetech Laboratories, Inc., Palo Alto, California (**Appendix A**, Bates No. 0003).

Next, prior to September 15, 1994, and as described on page 23, lines 7-8 of the present application, the library was plated by Nicole Nelson according to the procedures detailed in the manual provided by Clonetech (**Appendix A**, Bates No. 0004). The initial purpose of these efforts was to clone the cDNA for mouse LERK-3 (referred to as A2) and mouse LERK-4 (referred to as C6). However, instead a new mouse LERK molecule was discovered, i.e., mouse LERK-6.

Prior to September 15, 1994, and as described on page 23, lines 8-30 of the present application, probes, referred to as A2 (LERK-3) and C6 (LERK-4), were generated using standard techniques. Generally, polymerase chain reaction (PCR) (Mullis et al, *Meth. Enzymol.*, 155:335-350 (1987)) amplifications were performed by Carl Kozlosky (**Appendix D**, Bates Nos. 0036-0037) using two sets of primers. The first set of primers,

GATATTACT GCCCGCACTA CAACAGCT SEQ ID NO:3

AGAGAAGGCG CTGTAGCGCT GGAAC SEQ ID NO:4

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

was used to generate amplified double stranded DNA fragments from the DNA of LERK-3 (LERK-3, also known as hek-ligand, is the subject of U.S. Patent 5,516,658 (**Appendix B**, Bates Nos. 0008-0026) which issued from U.S. Patent Application Serial No. 08/240,124, filed May 9, 1994, and which claims benefit of Serial Nos. 08/109,745, 08/114,426 and 08/161,132). The probe from LERK-3 comprised nucleotides 260 through 481 of the SEQ ID NO:1 of U.S. Patent 5,516,658. The second set of primers,

ACGTAGTCTA CTGGAACTCC AGTAACCCCC G SEQ ID NO:5

AGCCTCAAGC ACTGGCCAGA ACTCTCTCTG GAGT SEQ ID NO:6

was used to generate amplified double stranded DNA fragments from the DNA of LERK-4 (LERK-4 also is the subject of U.S. Patent 5,516,658). The probe from LERK-3 comprised nucleotides 110 through 467 of the SEQ ID NO:3 of U.S. Patent 5,516,658.

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:3, i.e., oligo #12334 (also referred to as A2rib5.28) (**Appendix C**, Bates No. 0027), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0027).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:4, i.e., oligo #12333 (also referred to as A2T7.49) (**Appendix C**, Bates No. 0028), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0028).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:5, i.e., oligo #12312

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

(also referred to as C6RIBO5.31) (**Appendix C**, Bates No. 0029), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0029).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:6, i.e., oligo #12316 (also referred to as C6T7.54) (**Appendix C**, Bates No. 0030), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0030).

Oligonucleotides #12333 and 12316 also included nucleotides encoding the T7 polymerase promoter.

Prior to September 15, 1994, Carl Kozlosky identified the location of oligonucleotides #12334 (A2rib5.28) and #12333 (A2T7.49) in the LERK-3 DNA sequence, as shown in **Appendix D**, Bates Nos. 0032-0033; as well as the location of oligonucleotides #12312 (C6RIBO5.31) and 12316 (C6T7.54) in the LERK-4 DNA sequence, as shown **Appendix D**, Bates Nos. 0034-0035).

Thereafter, and prior to September 15, 1994, and as described on page 23, lines 30-35 of the present application, the PCR fragments (A2/LERK-3 and C6/LERK-4) were radiolabelled by Nicole Nelson with ^{32}P (**Appendix A**, Bates No. 0005), and used by Fred Fletcher as probes to screen the murine embryonic cDNA library prepared by Nicole Nelson by conventional procedures, and hybridizing clones were identified. Fred Fletcher was a Staff Scientist at Immunex Corporation at the time who worked on the LERK project under my direction and supervision. The hybridizing conditions consisted of 42°C and 50% Starks washed to 0.1X SSC at 63°C (**Appendix A**, Bates Nos. 0005-0006). In this manner, clone #13 was identified by Fred Fletcher on an X-ray

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

film, a copy of which was placed in Nicole Nelson's Laboratory Notebook (**Appendix A**, Bates No. 0007).

Then, and prior to September 15, 1994, and as described on page 23, line 35 and page 24, line 4, of the present application, the nucleotide sequence of the cDNA insert of clone #13 (λ 13), isolated from the murine embryonic cDNA library, i.e., mouse LERK-6 (mLERK6), was determined at my request by the core facility at Immunex Corporation, and the results were entered into a computer database, a printout of which, which was generated prior to September 15, 1994, is shown in **Appendix E**, Bates Nos. 0038-0039. DNA encoding the first ³ amino acids shown in **Appendix E** is derived from the sequencing vector, as indicated by the mark between the ^{ninth nucleotide} C & CCG and the ^{tenth nucleotide} G & CCG. ^{PC} ^{§ 171|2003} Also, the initiation codon Met is not shown in **Appendix E**. Thus, a substantially complete cDNA sequence of the coding region of the clone λ 13 cDNA, and the amino acid sequence encoded thereby were determined, and are presented in SEQ ID NO:1 and SEQ ID NO:2, respectively of the present application. The open-reading frame within this sequence in **Appendix E** (and within SEQ ID NO:1) encodes a protein of 184 amino acids beginning with the ^{first} ^{second} Ala. ^{§ 171|2003}

Prior to September 15, 1994, I carried out a comparison of the amino acid sequences of mouse LERK-6 v. human LERK-3 (also referred to as A2) (**Appendix E**, Bates No. 0040); mouse LERK-6 v. human LERK-4 (also referred to as C6) (**Appendix E**, Bates No. 0041); mouse LERK-6 v. human LERK-2 (also referred to as ELKL) (**Appendix E**, Bates No. 0042); mouse LERK-6 v. human LERK-5 (**Appendix E**, Bates No. 0043); mouse LERK-6 v. human LERK-1 (also referred to as B61) (**Appendix E**, Bates No. 0044); mouse LERK-6 v. mouse LERK-4 (also referred to as MC6) (**Appendix E**, Bates

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

No. 0045); as well as the DNA sequences for mouse LERK-6 v. human LERK-3 (A2) (**Appendix E**, Bates Nos. 0046-0047),); mouse LERK-6 v. mouse LERK-4 (MC6) (**Appendix E**, Bates No. 0048); and mouse LERK-6 v. human LERK-5 (**Appendix E**, Bates No. 0049). These comparisons showed many conserved amino acids and nucleotides amongst the family, and clearly showed that LERK-6 was a member of the LERK family of proteins, and thus would bind to hek/elk.

Prior to September 15, 1994, the results of the above-discussed experiments were presented by Nicole Nelson at an internal HEK/ELK meeting at Immunex Corporation. This meeting was chaired by Barry Davison in my absence, who prepared the meeting minutes, a copy of which is shown in **Appendix F** Bates No. 0050-0051.

Next, as described on page 24, lines 14-17 of the present specification, on July 15, 1994, a cell lysate containing clone λ13 DNA (the LERK-6 cDNA in λgt10) was deposited with the American Type Culture Collection, Rockville, MD, USA, and assigned accession number ATCC 75829. A copy of the deposit receipt is shown in **Appendix G**, Bates No. 0052.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

as Date: 2/20/01
Collected 8/7/2003
Pg 6

Name: Douglas P. Cerretti
DOUGLAS P. CERRETTI

Douglas P. Cerretti

NOTEBOOK NO. 7866
ISSUED TO Nicole Nelson
ON **19**
DEPARTMENT M/S
RETURNED **19**

—SCIENTIFIC NOTEBOOK CO.—
2831 LAWRENCE AVE.
P.O. BOX 238
STEVENSVILLE, MI 49127
616-429-8285

0001

IMMUNEX LABORATORY NOTEBOOK

"TABLE OF CONTENTS" FORM

Notebook #: 4266

Date form completed:

Form Completed by:

Nicole Johnson

MOLECULE(S):

c-MGF

H&L

AIK

LEAK 4

LEAK 3

PROJECT(S):

Product Analysis Certificate

PRODUCT: Mouse Embryo 5'-STRETCH cDNA Library

CAT. #: ML1027a

LOT #: 1211

STORAGE CONDITIONS:

SHORT-TERM STORAGE (< 6 MONTHS)
4°C

LONG-TERM STORAGE (> 6 MONTHS)
-70°C

SHELF LIFE:

1 year from date of receipt under
proper storage conditions

SHIPPING CONDITIONS:

Dry Ice (-70°C)

PACKAGE CONTENTS:

- 0.2 ml library lysate in 1X Lambda Dilution Buffer and 7% DMSO
- 0.5 ml host strain
- Lambda Library Protocol Handbook (PT101)

TITER: $\geq 10^8$ pfu/ml

CLONING VECTOR: λ gt10

CLONING SITE: EcoRI

PRIMING METHOD: oligo(dT)-primed

HOST STRAIN: C600 Hfr

mRNA SOURCE:

whole embryo (not including placenta, extraembryonic membranes) from a cross between ICR outbred females and outbred Swiss Webster males, 11.5 days post-coitus (noon on the day vaginal plug is 0.5 day post-coitus)

NOTE: No further information on the mRNA source was made available to CLONTECH.

QUALITY CONTROL DATA

SELECTION CRITERIA:

ESTIMATED

% OF CLEAR PLAQUES: 86%

NUMBER OF

INDEPENDENT CLONES: 1.7×10^6

AVERAGE INSERT SIZE: 1.5 kb

INSERT SIZE RANGE: 0.8-4.0 kb

Clear plaques from turbid plaques (nontoxic or parental)

(when plated on C600 before amplifying in C600Hfr)

AMPLIFICATION: This library was amplified once in C600 Hfr

APPROVED BY:

(PA93650-1)

0003

FOR RESEARCH USE ONLY

cDNA for 3rd C6

Book No.

Page No.

Titer Library

01

2A 3000 1.5 mm²

5A 1500 4.0 7.5%²

6A 1300 3.0²

1:500 1:250000
1:1000000

Plate the cells at 300²

1:5000000 1:500000 3.0% 3.0% = 1.5%
1:10000000

2A 6000 1:150 10:90 dilution 500² spot = 3.75% plate need 7.5%

8000 1:5000000

1A

Take a fresh dilution and plate at 5.75% plate (2) plated by 10:4

The plates did not grow in 8 hours I left them returned 11:01 they had grown to full size & the concentration was 10 fold less.

0004

To Page No. 8

Assessed & Understood by me,

Date

Invented by

Date

DNC

Recorded by S. L. Cleon

Project No. _____

Book No. _____

TITLE 5' strand DNA library Texine

From Page No. 83

Probes made for Fred Fletcher to use in sequencing

PROGRAM # 2X Scan 1/2 the second 2650 columns 01:44:00
 REGION A: LL-UL = 5-1700 LCR= 0 BKG= .00 % 2 SIGMA=.00
 REGION B: LL-UL = 50-1700 LCR= 0 BKG= .00 % 2 SIGMA=.00
 REGION C: LL-UL = 10-100 LCR= 0 BKG= .00 % 2 SIGMA=.00
 TIME= 1.00 K= 1.000 OIP=SIS

F# S# TIME CFMA/K %DEV CFMB/K %DEV CPMC/K %DEV SIE SIS FLAGS MIN
 151 1 1.00 481546.329 9757.00 2.02 .00 .00 1.000 41.386 160 112
 151 2 1.00 666133.125 22258.0 1.34 .00 .00 1.000 45.390 104 300

PROGRAM # 13 23:32
 REGION A: LL-UL = 5-1700 LCR= 0 BKG= .00 % 2 SIGMA=.00
 REGION B: LL-UL = 50-1700 LCR= 0 BKG= .00 % 2 SIGMA=.00
 REGION C: LL-UL = 10-100 LCR= 0 BKG= .00 % 2 SIGMA=.00
 TIME= 1.00 K= 1.000 OIP=SIS

F# S# TIME CFMA/K %DEV CFMB/K %DEV CPMC/K %DEV SIE SIS FLAGS MIN
 303 1 1.00 389178.132 6839.00 2.42 .00 .00 1.000 37.510 172 172
 303 2 1.00 293853.137 4696.00 2.92 .00 .00 1.000 35.396 172 300

These probes mixed with the positive controls included in the hybridization set. Fred Fletcher's files

0005

To Page No. 8

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

1. 94

Normal embryo

cDNA library

probed w/ A2, C6

and GST- β .

probed 42°C on streaks

washed to 1X SSC - 63°

1° filts

from Fast Filtration

re plated to 96 library before Xmas 93

removed these filters

0006

Mu. DNA 2^o dilutions

1.0M 42° 2 hrs
RT 0.1M SDS STARKS 1.2M C6 H₁₂L
Wash RT 6X SSC .1% SDS .P₁₀ GSP riboprobe
6.5° 1X SSC .. 60'
6.5° 0.1X SSC .. 20'
2xP 3mgs 42°C/87



1000 100 1019
1000 100 517
1000 100 517
1000 100 517
1000 100 517
1000 100 517
1000 100 517
1000 100 517

0007

Oligo Name: A2RIB5.28

Sequence Requested by: KOZLOSKY
Project name: ELK

Date Requested:

DNA Sequence (5'-3'): 5'-GAT ATT TAC TGC
CCG CAC TAC AAC AGC

Date Synthesized:

PURIFICATION: PHENOL

(28 bases) 8A's 4G's
9C's 7T's

COMMENTS:
A2 5' PRIME PCR OLIGO FOR
MAKING A α^{32} RIBOPROBE.

A2rib5.28

R7043

1' GATATTACT GCGCGACTA AACAGCT

Column 2

9:44:32A

Run ID :

Cycle : 40PLUS CYC

End Freq: End CE (DMT = On)

Sequence: 12334

Total bases = 28

A= 8, G= 4, C= 9, T= 7, 5= 0, 6= 0, 7= 0, 8= 0
(mixed bases= 0)

MW: 8489.6

5' > GAT ATT TAC TGC CCG CAC TAC AAC AGC T <3'

Purification: OPC

Amount of crude: all

O.D.260: 1.606

dilution factor: 1:500

concentration:

yield:

10.09ug/l

100.9 μ g

get on
back

0027

Oligo NAME: A2T7.49

Sequence Requested by: KOZLOWSKI
Project name: ELK

Date Requested:

Oligo number: 12333

Date Synthesized:

DNA Sequence (5'-3'): 5'-TGC GAA TAA TAC
GAC TCA CTA TAG AGA
GAA GGC CCT GAA CG
CTG GAA C-3'

PURIFICATION: PHENOL

(49 bases)

16A'5 14G'5
10C'6 9T'5

OPC

COMMENTS:
3 PRIME A2 OLIGO TO PCR
A T7 RIBOPROBE. THIS
OLIGO IS ANTISENSE AND
CONTAINS THE T7
PROMOTER.

A2t7.49

R7044

1 TGC GAA TAA TAC GAC TCA CTA TAG AGA GAA GGC CCT GTC GAA AC

Column 1

9:44:31A

Run ID :

Cycle : 40PLUS CYC

End Proc: End'CE (DMT = On)

Sequence: 12333

Total bases = 49

A= 16, G= 14, C= 10, T= 9, S= 0, 6= 0, 7= 0, 8= 0
(mixed bases= 0)

MW: 15174.8

5' > TGC GAA TAA TAC GAC TCA CTA TAG AGA GAA GGC CCT GTC

GCG CTG GAA C - 3'

Purification: OPC

Amount of crude: all

O.D.260: 2.76

dilution factor: 1:500

concentration: 4.00 μg/λ

yield: 4.00 μg

gel on
12334

0028

Oligo NAME: C6RIBOS.31 Oligo number:
Sequence Requested by: KOZLOSKY
Project name: ELK
Date Requested:
DNA Sequence (5'-3'): 5'-ACG TAG TCT ACT
GGA ACT CCA GTA ACC
CCA G-3'
PURIFICATION: (31 bases) 9A's 6G's
~~OPC~~ 10C's 6T's
COMMENTS:
5 PRIME PCR FOR C6 RIBO

R7023

Column 2

2:45:43F

Op ID: 40PLUS CFC
Title: 40PLUS CFC
End Fract: End CE (DMT = On),
Sequence: 12312
Bo

Applied Biosystems G 209118

total bases = 31

A= 7, G= 6, C= 10, T= 5, S= 0, o= 0, ?= 0, E= 0
(mixed bases= 0)

W: 9444.2

5'-ACG TAG TCT ACT GGA ACT CCA GTA ACC CCA G-3'

Purification: OPC

Amount of crude: all

O.D.260: 0.382

dilution factor: 1-500

concentration: 6.36 ug/


yield: 636 ug

get on

12,334

0029

Oligo NAME: C6T7.54 Oligo number: 12316
Sequence Requested by: KOZLOSKY
Project name: ELK
Date Requested:
DNA Sequence (5'-3'): 5'-TGC GAA TAA TAC
GAC TCA CTA TAG CCT
CAA GCA CTG GCC AGA
ACT CTC TGG AGT -3'
(54 bases) 16A's 11G's
PURIFICATION: ~~ethanol~~ OPC 15C's 12T's
COMMENTS:
C6 3 PRIME FOR C6 RIBO
USE T7 POL.
R7024

Applied Biosystems T 453741


COLUMN 2 SET-UP
VERSION 2.02

USER_NAME:
CYCLES USED: 0.3UMB = ;
ENDING METHOD: Trityl ON, Auto
ENDING PROCEDURE: deprime
SEQUENCE NAME: 12316
SEQUENCE LENGTH: 54
DATE:
TIME: 17:37
COMMENT:

5'- TGC GAA TAA TAC GAC TCA CTA TAG CCT CAA GCA CTC

600 896 ACT CTC 166 AGT -3'

yield:

OPC
all
0.303
1.500
5.04 ug/
5.04 ug

gel on
12334

0030

IMMUNEX LABORATORY NOTEBOOK
"TABLE OF CONTENTS" FORM

Notebook #: 3388 Date form completed:

Form Completed by: Carl Kozlosky

MOLECULE(S): B61, ELK, ELK-L, HEK,
lck's 1, 2, 3, 4, 5, 7

PROJECT(S): R150L


~~(Lines) (Six Base) MAP of: A2.Seg check: 6473 from: 1 to: 1037~~

~~REKL~~
CLONE A2
SEQ REQ 1741
DIR= [JOHNSONL.HEKL]

With 114 enzymes.

T7 is 5' end
BglII into BamHI

09:13



1 26 P P
 / 1 B
 1 2 C
 GGATCTTGGAACGAGACGACCTGCTGGAGAAGCCGGAGCGGGCTCAGTCGGGGGGCGGGGGCGGGGGCTCGGGGATGGCGGCGGCTCGCTG
 CCTAGAACCTGCTCTGCTGGACGACCTCTGGCCCTCGGCCCGAGTCAGCCCCCGCCGCCGCGCGAGGCCCCTACOGCGCCGAGGCGAC + 100
 AspLeuGlyThrArgArgProAlaGlyGluAlaGlySerAlaGlyLeuSerArgGlyAlaAlaAlaAlaAlaProGlyMetAlaAlaAlaProLeu
 B

101 CTCCTGCTGCTGCTCGTCCCCGTGCCGTGCTGCCGTGCTGGCCCAAGGGCCGGAGGGCGCTGGAAACGGCATCGGGTGTACTGGAACAGCT
 + 200 GACGACGACGACGAGCACGGCACGGCGACGACGGCTCCGGGCTCCCGCGACCCCTTGGCGTAGGCCACATGACCTTGCGA
 LeuLeuLeuLeuLeuLeuValProValProLeuLeuLeuAlaGlnGlyProGlyGlyAlaLeuGlyAsnArgHisAlaValTyrTrpAsnSerSer
 A B B
 1 5

CCAACAGCACCTGGCGAGAGGGTACACCGTCAGGTGAACTGAACGACTATCTGATATTACTGCCCCACTACACAGCCTGGGGTGGGCC
 201 GGTGGCTGGACGCCGCTCTCCCGATGGGCAGTCCACTGCACTTGTGATAGACCTATAAATGACGGGCGTGATGTTGTOAGCCCCCACCGGG
 AsnGlnHisLeuArgArgGluGlyTyrThrValGlnValAsnValAsnAspTyrLeuAspIleTyrCysProHisTyrAsnSerSerGlyValGlyPro
 B B
 1 2 11 300

B	B	SerValAsnAspTyrLeuAspIleTyrCysProHisTyrAsnSerSerGlyValGlyPro				
s	s					
p8	B p	B				
B1sPSX	D sAB1P	s				
a2rsmu	r rpa2s	a				
n8fsea	a Fan8s	A				
261111	2 11261	1				
caggGAGGGACAGGGGCCGGAGGCGGGCAGAGCACTT						

101 CUGGGA~~G~~GGGACCGGGGCCGGAGGCGGGCAGAGCAGTACGTQCTGTACATGGTGAGCCCAA|CGGCTACCGCACCTGCAACGCCAGCCAGGGCTTCAG
GCCCGGCCCTGGCCCCGGGCCTCCGCCCCGTCCTGTCATGCAAGACATGTACCACTCGGCGTGGCGATGGCGTGGACGTTGGCGTGGCGTGGCGTACCGAAGTTC
GlyAlaGlyProGlyProGlyGlyGlyAlaGluGlnTyrValLeuTyrMetValSerArgAspGluTyr

E **C** **S** **H** **L** **D** **T** **Y** **M** **V** **A** **S** **R** **G** **A** **N** **G** **Y** **T** **Y** **T** **A** **R** **G** **T** **H** **R** **C** **s** **A** **n** **A** **s** **R** **G** **I** **G** **Y** **P** **h** **L** **y**

4 a
7 e
3 2

7 *c
3 21 2

ArgTrpGluCysAsnArgProHisAlaProHisSerProIleLysPheSerGluLysPheGlnArgTrpSer

E S B X B
 a c p m n r
 e e M I
 i 1
 CCGGCCACGGACTACTACATCTCCGCGCGC
 CCGGCCACGGACTACTACATCTCCGCGCGC

AZTF, 49

0032

TITLE


AZ Sqg.

Project No. _____

Book No. _____

62

From Page No. _____



To Page No. _____

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by

OPC


0033

(Line*) (Six Base) MAP of: C eq check: 9352 from: 1 to: 636

HeKL 132-11, C6-no vector
2491,T7,DPC3266,DPC3267,DPC3274,DPC3275
SR1810 KOZLOSKY
file: (BERTLESJ.HEKL)C6.SEQ

With 114 enzymes:

12:12 ...



B
S
P
B1
a2
m
26
/

1 GCCAGACCAACCGGACCTGGGGCGATGCGGCCTGCGCCCTGCTGGGACTGTCTCTGGGGCGGTTCTCGGTCGCCCTGCGGGGGCTCCA
100 CGGTCTGGTGTGGCTGGAGCCCCGCTACGCCGACGCCGAGACGCCGCTGACAGGAGACCCGGCAAGGAGCAAGGAGAGCGGCCCCGAGGT

a: AlaArgProAsnArgThrSerGlyAlaMetArgLeuLeuProLeuLeuArgThrValLeuTrpAlaAlaPheLeuGlySerProLeuArgGlyGlySerSer

101 B E B
Bs A s D
pa C R 5 s
mA c 3 a
11 1 C6 RIBO-31 1 1
100 200
101 CGGAGCGGTGCATCAGATGACCTTGAGGTATTGGGTCCAAAGAACGCTCTGGCGACCACCTGACCCGGAGTGTCTAATGGATCTGTAACAGAC

a: LeuArgHisValValTyrTrpAsnSerSerAsnProArgLeuLeuArgGlyAspAlaValValGluLeuAsnAspTyrLeuAspIleValCys

200 B B E B E B DD PAAB
sB s P D a a DD PAAB
ps E P a a rr spa
DD PAB1P DdsPAABB1P aa saan
rr spa23s rrpsspvac2s e 1 22 1112
aa san86s aa3saang8s 1 1 /
22 112611 221112161 // / // /

201 300
CCCCCACTAGGAAGGCCAACGGGCCCTGAGGGCCCGAGACGTTGCTTGTACATGGTGGACTGGCCAGGCTATAGTCTGCCAGGCAGAGGCC
CCCCCGATGTTGGCGACCCACAGAGGGACGGGAAACCGTACAAGTTAAGAGTCTCTCTAAGTGGCAAGTGTGAAAGAGGGAGCCAACTCAAGA

a: ProHisTyrGluGlyProGlyProGluGlyProGluThrPheAlaLeuTyrMetValAspTrpProIsoleTyrHisSerSerIleAlaIsoleTyr

300 B B E B E B DD PAAB
s E s C a a DD PAAB
pB C pH o H rr spa
1sPSX o H 1g E B a a
2rsPSX 4 a 2i a a 22 1112
8PSX 7 e 8A e l /
611h 3 2 61 1 1 3 2
// / / / / / /

301 400
CGGGCTACAGGCTCGTGTGCTCCCTGGCATGTTCAATTCTCAGAGAAGATTAGCGGCTCACACCTTCCTGGCTTGAGTTCT
CCCCGGATGTTGGCGACCCACAGAGGGACGGGAAACCGTACAAGTTAAGAGTCTCTCTAAGTGGCAAGTGTGAAAGAGGGAGCCAACTCAAGA

a: ArgAlaTyrLysArgTrpValCysSerLeuProPheGlyHisValGlnPheSerGluLysIleGlnArgPheThrProPheSerLeuGlyPheLeu

400 B B B B T EBB
s s p t EBB
p p a 2 h apa
m m 8 3 eml
1 1 1 6 2 111
TACCTGGAGAGACTACTACATCTGGTGGCCACTCGAGAGTTCTGGCCAGTGTGAGGTTCCAGGTTGAGGTTCTGGCTCAAGGAGAGGAAGTC
ATGGACCTCTGAATGATGATGAGGCCACCGGAGGTCTCAAGACCGGTACAGACTUCAGGTCCACAGACAGACAGGCTTCCTCTGAGTCAG

a: ProGlyGluThrTyrTyrTyrIleSerValProThrProGluSerSerGlyGlnCysteLeuArgLeuGlnValSerValCysCysLysGluArgLysSer

500 GATAATCAUTLAGCAIAATAAGCGT
C677.54

501 600
TGAGTCAGGCTACATCTGGTGGAGAGAGTGGCACATCAGGGTGGAGAGGGGGAGACTCCAGGCCCCCTGTGTGTGTGAGTATTACTCTG
ACTCACTGGTGGAGACACACCTGGGACCTCTCACCGTGTAGTCCACCGCTCCCCCTGAGGGTGGGGAGACAGAGAACGATAATGACGAC
TCTAG

179aa 20kd

0034

TITLE


Cb S&G.

Project No. _____

Book No. _____

From Page No. _____

66




A large hand-drawn circle with a diagonal cross through it, centered on the page.

Witnessed & Understood by me,	Date	Invented by	To Page No.
9pc		John Gosselby	
		Recorded by	

0035

TITLE Cb T7 Ribo PCR Project No. _____
Book No. _____

From Page No. _____



*Cb Binding Region
T7 RNA Pol*

Witnessed & Understood by me.		Date	Invented by	<i>Carl H. Hogenkamp</i>	Date	To Page No.
<i>PPC</i>			Recorded by	<i>Carl H. Hogenkamp</i>		

0036

TITLE

C6 Nth

Project No. _____
Book No. ____

From Page No. ____

< 189 ~ 1.6 Kb w HSB-2



NW A2 T7
Raboprobe
Template

Witnessed & Understood by me.

Orc

Date

Invented by

Recorded by

To Page No. ____

Date

0037

Working File
Do Not Copy!

With 114 enzymes: *

13:38

B

s

E	B	pB
Ac	s	AAB1sSSX
po	r	vpa2rmr
oR	F	aan8Fafa
11	l	11261111
/		

A

c

c

c

1

E

c

o

H

4

a

7

e

3

2

1 GAATTCCGGGCCGGGCAACGCTGACCAGTACCGAGTCTACTGGAACCGTAGCAACCCCAGGTTTCAGGTGAGCAGCTGTGGGTATGGCGCGGCTATA
1 CTTAAGGCCGGGCCGGTGCAGACTGGCATCGCTAGATGACCTTGGCAAGTCCACTCGCACACCCACTACCGCCGATAT 100

a: GluPheArgAlaArgAlaAsnAlaAspArgTyrAlaValTyrTrpAsnArgSerAsnProArgPheGlnValSerAlaValGlyAspGlyGlyGlyTyrThr -

B

p

u

D	E	B	N	1
s	c	BsKNH	s	1
a	o	aaaaa	p	0
1	R	nHsre	B	2
/				
11112 2				

101 CCGTGGAGGTGAGCATCAACGACTACCTGGATATCTACTGCCACACTACGGGGCGCGCTGCCCCCGGCTGAGCCATGGAGCGGTACATCCTGTACAT

101 GGCACTCCACTCGTAGTTGCTGATGGACCTATAGATGACGGGTGTGATGCCCGCGACGGGGCCGACTCGCTACCTCGCCATGTAGGACATGTA 200

a: ValGluValSerIleAsnAspTyrLeuAspIleTyrCysProHisTyrGlyAlaProLeuProProAlaGluArgMetGluArgTyrIleLeuTyrMet -

E

c

o

H

4

a

7

e

3

2

B P

AsHSX Dp P

vramn ru s

aFeaa aM s

11211 21 1

11111 /

201 GGTGAATGGTGAGGGCCACGGCTCTGTGACCAACGGCAGCAGGCTTCAAAGGGCTGCGATGCAACCCGGCCAGGGCCGGGGGAGCCTCAAGTTC
201 CCACITAACTCCCGCTCGGGAGGACACTGGTGGCGTCGCTCCGAAGTTCGCGACCCCTACGTTGGCCGGCGTCGCGGGCCCCCTGGGAGTTCAAG 300

a: ValAsnGlyGluGlyHisAlaSerCysAspHisArgGlnArgGlyPheLysArgTrpGluCysAsnArgProAlaAlaProGlyGlyProLeuLysPhe -

B

s

t

X

1

301 TCAGAGAAGTTCCAACCTTCCACCCCTTCCCTGGCTTGAGTTCCGGCCACGAATACTACTACATCTCTGCCACACCTCCAACCTCGTGG
301 AGTCTCTCAAGGTGAGAAGTGGGGAAAGGGACCCGAAACTCAAGGCCGACCGGTGCTTATGATGATGTAGAGACGGTGTGGAGGGTTGGAGCACC 400

a: SerGluLysPheGlnLeuPheThrProPheSerLeuGlyPheGluPheArgProGlyHisGluTyrTyrIleScrAlaThrProProAsnLeuValAsp -

B

s

1

2

3

4

5

A

N

6

7

8

9

10

11

12

401 ACCGACCCCTGCCCTGGACTCAAGGTTATGTGCGTCCACCAATGAGACCCCTGTATGAGGCTCCAGAGCCCATCTTACCGAGTAACAGCTCTGCAGCGG
401 TGGCTGGGACGGACGGCTGAGTCCCAAATACAGCGAGGTTGTTATCTGGGACATACTCCGAGGTCTGGGTAGAAGTGGTCAATTGTCGAGGACGTCGCC 500

a: ArgProCysLeuAraLeuLysValTyrValArgProThrAsnGluThrLeuTyrGluAlaProGluProIlePheThrSerAsnSerSerCysSerCys -

B

1

2

3

4

5

6

7

8

9

10

11

12

501 CCTGGGTGGCTGCCACCTCTTCCCTACCAACGGTCCCTGTGCTGTGGCTCCCTCTGGGCTCCTAGTGTGAGGCGGGAGAACACCAGCCCCACCTGGACCC
501 GGACCCACCGACGGTGGAGAAGGAGTGGTGGCAGGGACACGACACCAGGGAGACCCGAGGATCACAGTCCGGCTTGTGGTCGGGTGGACCTGGGG 600

a: LeuGlyGlyCysHisLeuPheLeuThrThrValProValLeuTrpSerLeuLeuGlySerEndCysGlnAlaGlyGluHisGlnProHisLeuAspPro -

B
D Es
s ap
a eM
l 11

601 GTGACCTTGCCCTCTGACCTGCCACGGCCACCTCCGAGACAAATCCTGCTGCTCTTTATGGTGTGCTCCCAGGGAGGCCATCCATCCGT
CACTGGAAACGGGAGACTGGACGGTGCCTGGAGGCTCTGTTTAGAACGAAAGAGAAAGTACACGACAGGGCGCCTCCCGTAGGTAGGCA
a: ValThrPheAlaLeuEndProAlaThrAlaSerGluThrLysSerLeuLeuLeuLeuPheHisGlyAlaValProProGluGluAlaIleHisProSer -

P	B											
Dp P	s											
ru s	u											
aM s	3											
21 l	6											
	1											
		b	t									
				s	y							
					1	1						
							BS					
							gf					
							li					
							11					
							/					

701 CCCTGGGATGCAAATGGGGTCCAATGCCTGAGGAGAACCCCCCCCCAAGGCTGACTCGCTTACCAAGGGCACAGGGCCATCCAGTGTGYATA
GGGACCTACGTTGTACCCAGGGTACGGACTCCTCTGGGGGGGGTCCGACTGAGCGAAAGTGGTCCCGTAGGTACAACRTAT
a: LeuGlyCysAsnMetGlySerGlnCysLeuArgArgArgProProProLysAlaAspSerLeuSerProGlyProProGlyProSerSerVal??End -

ATTCTT
801 ----- 807
TAAGAAA

a: PhePhe -

Enzymes that do cut:

Acc1	AlwN1	Apol	Apal	Aval	Bal1	Ban1	Ban2	Bbs1	Bgl1	Bpu11021	Bpm1	Bsal
BsaH1	Bsm1	Bsp1286	BspM1	BsrF1	BstX1	Bsu361	Dra2	Dsal	Eael	Earl1	Eco473	EcoN1
EcoR1	EcoR5	Hae2	Kas1	Nar1	NspB2	PpuM1	Pss1	Pst1	Sfc1	Sfil	Smal	Srf1
Styl	Xma1											

Enzymes that do not cut:

Aat2	Afl12	Af13	Age1	ApaL1	Ascl	Asel	Asp718	Asu2	Avr2	BamH1	Bcg1	Bcl1
Bgl2	BsaAl	BsaB1	BsiE1	BsiW1	BspE1	BspH1	BssH2	Bst1107	BstE2	Cla1	Dra1	Dra3
Drd1	Eam1105	Eco571	Esp31	Fsp1	HgiAl	Hinc2	Hind3	Hpa1	Kpn1	Mlu1	Mun1	Ncol
Nde1	NgoM1	Nhe1	Not1	Nru1	Nsil	NspH1	Pac1	PflM1	Pme1	Pml1	Pvu1	Pvu2
Rsr2	Sall	Scal	SgrAl	SnaB1	Spe1	Spol	Sse8387	Ssp1	Sst1	Sst2	Stu1	Swal
Tth31	Tth32	Xba1	Xcm1	Xho1	Xba2	Xba3	Xba1					

0039

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: A2.Pep check: 4723 from: 1 to: 238

TRANSLATE of: a2.seq check: 6473 from: 83 to: 796
generated symbols 1 to: 238.

HEKL

CLONE A2

SEQ REQ 1741

DIR= [JOHNSONL.HEKL] . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapppe.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 137.9 Length: 246
Ratio: 0.741 Gaps: 6
Percent Similarity: 67.416 Percent Identity: 48.876

Mlerk6.Pep x A2.Pep 16:30 ..

1	RARANADRYAVYWNRSNPRFQVSAVG	26
		.. :: . . .::	
1	MAAAPLLLLLILLPVPVPLPLL	AQGPAGALGNRHAVYWNSSNQHLRR	46
27	DGGGYTVEVSINDYLDIYCphyGAPLPPAERMERYILYMVNGE	69
	: : .:	. . :: . : . . :	
47	..EGYTVQVNNDYLDIYCphy	NSSGVGPGAGPGPGGGAEQYVLYMVSRN	94
70	GHASCDHRQRGFKRWE	CNRPAAPGGPLKFSEKFQLFTPFLGFEFRPGHE	119
	. . : .	: : :: : :	
95	GYRTCNASQ.GFKRWE	CNRPHAPHSPPIKFQRYSAFSLGYEFHAGHE	143
120	YYYISATPPNLVDRPCRLKVYVRPTNETLYEAPEPIFTSNSSC	163
	..: .:. : :: . : .:. 	
144	YYYIS.TPTHNLHWKCLRMKV	FVCCASTSHSGEKPVPTLPQFTMGPNVKI	192
164	SGIGGCHLFLTTVPVI..WSLLGS*	186
	.. : : . . . : .		
193	NVLEDFEGENPQVPKLEKSISGTSPKREHLPLAVGIAFFILMTFLAS		238

0040

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: C6.Pep check: 8194 from: 1 to: 201

TRANSLATE of: c6.seq check: 6086 from: 53 to: 655
generated symbols 1 to: 201.

HEKL 132-11, C6-no vector
2491, T7, DPC3266, DPC3267, DPC3274, DPC3275
SR1810 KOZLOSKY
file: [BERTLESJ.HEKL]C6.SEQ . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapppe.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 118.5 Length: 216
Ratio: 0.637 Gaps: 7
Percent Similarity: 61.988 Percent Identity: 46.199

Mlerk6.Pep x C6.Pep 16:31 ..

1 RARANAD.RYAVYWNRSNPRFQVSAVGDGGGY 31
1 MRLLPLLRTVLWAAFLGSPLRGSSLRHVVYWNSSNPRLL....RGDA 44
32 TVEVSINDYLDIYCPHYGAPLPPAERMERYILYMVNGEHASCD.HRQRG 80
45 VVELGLNDYLDIVCPHYEGPGPPEGP.ETFALYMDWPGYESCQAEGPRA 93
81 FKRWECKRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISATPPNL 130
94 YKRWVC...SLPFGHVQFSEKIQRFTPFSLGFEFLPGETYYYISVPTPES 140
131 VDRPCLRLKVVVRPTNETLYEAPEPIFTSNSSCSGLGGCH..... 170
141 SGQ.CLRLQSVVCCKERKSESAHPVGSPGESGTSGWRGGDTPSPLCLLLL 189
171 LFLTTVPVILWSLLGS* 186
190 LLLLILRLLRIL.... 201

GAP of: Mlerk6.Pep che : 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: Elkl.Pep check: 1665 from: 1 to: 240

TRANSLATE of: tele7.seq check: 2210 from: 308 to: 1345
generated symbols 1 to: 346.

[hollingsworth.tele7] ELKL-E7.SEQ + ELKL-E7-3PRIME.SEQ;
req#1262

mGel 97 #2491+ #2492- mGel101 DPC2236+ DPC2239+/ mGel104 DPC2258+
DPC2257-/mGel105 DPC2261- /mGel107 DPC2271+ 2272- 2273- 2274+

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapppe.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 82.7 Length: 248
Ratio: 0.445 Gaps: 6
Percent Similarity: 46.067 Percent Identity: 28.652

Mlerk6.Pep x Elkl.Pep 16:46

1 RARANADR.....YAVYWNRSNPRFQVSAVG.....DGGGY 31
 . ||:.. : :|::: . .:::|: . | |.
 1 MARPGQRWLKGWLVAMVVWALCRLATPLAKNLEPVWSLNPKFLSGKGL 50
 .
 32 TVEVSINDYLDIYCPHYGAPLPPAERMERYILYMVNGEHHASCDHRQRGF 81
 . : ..|.| |||.||: :|.. | | | ||:|.. . | |.
 51 VIYPKIGDKLDIICPRAEAGR....YEYYKLYLVRPEQAAACSTVLDPN 96
 .
 82 KRWECKRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISATPPNLV 131
 . ||| |:...:|. ||| |. | :|:||:. |:||..|.. . .|.
 97 VLVTCNR...PEQEIRFTIKFQEFSPPNYMGLEFKHHDDYYITSTSNGSLE 143
 .
 132 D.....RPCLRLKVVVRPTNETLYEAPEPIFTSNSSCSGLGGCHLFL 173
 : . . . :|:...:|. .||: | |..| .: . .:
 144 GLENREGGVCRTRMKIIMKVGQDPNAVTPEQLTTSRPSKEADNTVKM.A 192
 .
 174 TTVPVLWSLLGS*..... 186
 | .| . :| |.
 193 TQAPGSRGSLGDSDGKHETVNQEEKSGPGASGGSSGDPDGFFNSKVAL 240

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: Lerk5.Pep check: 8553 from: 1 to: 240

TRANSLATE of: lerk5.leg check: 889 from: 1 to: 1002
generated symbols 1 to: 334.
Coding region of human LERK-5.

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapppe.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 83.2 Length: 250
Ratio: 0.447 Gaps: 5
Percent Similarity: 47.727 Percent Identity: 27.841

Mlerk6.Pep x Lerk5.Pep 16:59 ..

1	RARANADRY....AVYWNRSNPREFQVSAVGDG	28
1	MAVRRDSVWKYCWGVLMLCRTAISKSIVLEPIYWNSNSKFL....PG	45	.
29	GGYTVEVSINDYLDIYCPHYGAPIPPAERMERYILYMVNGEHA	CDHRQ	78
46	QGLVLYPQI	GDKLDIICPKVDS..KTVGQYEYYKVYMVDKDQADRCTIKK	93
79	RGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEY	YYISATPP	128
94	NTPLLNC...AKPDQDIKFTIKFQEFS	PNLWGLEFQKNKDYYIISTNSG	140
129	NLVD.....	RPCLRLKVV	141
141	SLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPE	LEAGTN	190
142	VRPTNETLYEAPEPIFTSNSSCSGLGGCHLFLTTVPVLWSLLGS*	186
191	GRSSTTSPFKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIV		240

Mlerk6.Pep clck: 6430 from: 1 to: 187

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE

DO NOT COPY!

to: B61.Pep check: 4381 from: 1 to: 205

TRANSLATE of: b61.seq check: 6304 from: 74 to: 688
generated symbols 1 to: 205.

LOCUS HUMB61 1480 bp ss-mRNA PRI
DEFINITION Human B61 mRNA, complete cds.
ACCESSION M57730 M37476
KEYWORDS intermediate-early response gene. . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapppe.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 128.5 Length: 212
Ratio: 0.691 Gaps: 4
Percent Similarity: 59.218 Percent Identity: 45.251

Mlerk6.Pep x B61.Pep 16:29 ..

1 RARANADRYAVYWNRSNPRFQVSAVGDGGGYTVEVSIN 38
1 MEFLWAPLLGLCCSLAAADRHTVFVNNSNPKFR.....NEDYT1HVQLN 44
39 DYLDIYCPHYGAPLPPAERMERYILYMVNGEGHASCDDRQRGFKRWECKNR 88
45 DYVDIICPHYEDHSVADAAMEQYILYLVEHEEYQLCQPQSKDQVRWQCNR 94
89 PAAPGGPLKFSEKFQLETPFSLGFEFRPGHEYYYISATPPNLVDRPCLRL 138
95 PSAKHGPEKLSEKFQRFTPFTLGKEFKEGHYYYISKPIHQHEDR.CLRL 143
139 KVYVRP.....TNETLYEAPEPIFTSNSSCSGLGGCHIF.LTTV 176
144 KVTVSGKITHSPQAHVNPQEKRRAADDPEVRLHSIGHSAAPRLFPLAWT 193
177 PVLWSLLGS*.. 186
194 VLLIPLLLQTP 205

Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: Mc6.Pep check: 7024 from: 1 to: 168

TRANSLATE of: mc6.seq check: 5844 from: 2 to: 505
generated symbols 1 to: 168.

Sequence of murine C6 (LERK-4) as derived from the genomic
clone (3.5 kbp Sst1 fragment).

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 111.3 Length: 196
Ratio: 0.663 Gaps: 7
Percent Similarity: 65.190 Percent Identity: 45.570

Mlerk6.Pep x Mc6.Pep 16:31 ..

1 RARANADRYAVYWNRSNPRFQVSAVGDGGSYTVEVSINDYLDIYCPHYGA 50
1LLRGDAV.....VELGFNDYLDIFCPHYES 25

51 PLPPAERMERYILYMVNGEG.HASCDHRQRGFKRWECKRPAAPGGPLKFS 99
| ||.: | : ||||: .| .|:... .:| .||: .|| | :||:||
26 PGPPEGP.ETFALYMWDSGYEACTAEGANAFQRWNCSMPFAPFSPVRFS 74

100 EKFQLFTPFSLGFEFRPGHEYIISATPPNLVDRPCLRLKVVVRPTN.ET 148
||:| :||.||||| ||..|||||.||: .:| ||||.|| | ...: .
75 EKIQRYTPFPLGFEFLPGETYYYISVPTPESPGR.CLRLQSVVCCKESGS 123

149 LYEAPEPI.FTSNSSCSGLGGCH.....LFLTTVPVLWSLLGS* 186
.||.:|: .:|:||: .| | :| :|: | .

124 SHESAHPVGSPGESGTSGWRGGHAPSPLCLLLLLLPILRLLRVL. 168

Mlerk6.Seq check: 8999 from: 1 to: 797

WORKING FILE
DO NOT COPY!

to: A2.Seq check: 9214 from: 1 to: 987

HEKL
CLONE A2
SEQ REQ 1741
DIR= [JOHNSONL.HEKL]

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapdna.Cmp
CompCheck: 6876

Gap Weight: 5.000 Average Match: 1.000
Length Weight: 0.300 Average Mismatch: 0.000

Quality: 362.8 Length: 1011
Ratio: 0.455 Gaps: 9
Percent Similarity: 56.016 Percent Identity: 56.016

Mlerk6.Seq x A2.Seq 16:33 ..

1	CGGGCCCGGGCCAACGCTGAC	21
101	TGCCGCTGCTGCCGCTGCTGGCCCCAAGGGCCGGAGGGCGCTGGGAAAC		159
22	CGATACGCAGTCTACTGGAACCGTAGCAACCCCAGGTTTCAGGTGAGCGC		71
151	CGGCATGCGGTGTACTGGAACAGCTCCAACCAGCACCTGCGG.....		192
72	TGTGGGTGATGGCGGGCTATAACCGTGGAGGTGAGCATCAACGACTACC		121
193CGAGAGGGCTACACCGTGCAGGTGAACGTGAACGACTATC		232
122	TGGATATCTACTGCCAACACTA.....	CGGGGCG	150
233	TGGATATTTACTGCCCGACTACAACAGCTGGGGTGGCCCCGGGCG		282
151	CCGCTGCCCGGCTGAGCGCATGGAGCGGTACATCCTGTACATGGTGAA		200
283	GGACCGGGGCCGGAGGCAGAGCAGTACGTGCTGTACATGGTGAG		332
201	TGGTAGGGCCACGCCCTCTGTGACCAACGGCAGCGAGGCTCAAGCGCT		250
333	CCGCAACGGTACCGCACCTGCAACGCCAGCAG...GGCTCAAGCGCT		379
251	GGGAATGCAACCGGCCAGCGCCCCGGACCCCTCAAGTTCTCAGAG		300
380	GGGAGTGCAACCGGCCGACGCCCGCACAGCCCCATCAAGTTCTGGAG		429
301	AAGTTCCAACCTTCACCCCTTTCCCTGGCTTGAGTTCCGGCTGG		350
430	AAGTTCCAGCGCTACAGCGCTCTCTGGCTACGAGTTCCACGCCGG		479
351	CCACGAATACTACTACATCTGCCACACCTCCAACCTCGTGGACCGAC		400
480	CCACGAGTACTACTACATCTCACGCCCACTCACAAACC...TGCAC		526

0046

448 TATGAGGCTCCAGAC ||CATCTTCAACCAGTAACAGCTCCTGC 489
577 GGGGAGAAGCCGGTCCCCACTCTCCCCAGTTCACCATGGGCCCAATGT 626
490 AGCGGCCTGGGTGGCTGTCACCTCTTCCTCACCAACCGTCCCTG 532
627 GAAGATCAACGTGCTGGAAGACTTGAGGGAGAGAACCCCTCAGGTGCCA 676
533 TGCTGTGGTCCCTCTGGGCTCCTAGTGTCAAGGCCGGAGAACACCAGCCC 582
677 AGCTTGAGAAGAGCATCAGCGGGACCAGCCCCAACGGGAACACCTGCC 726
583 CACCTGGACCCCGTGACCTTGCCCTCTGACCTGCCACGGCACCTCCGA 632
727 CTGGCCGTGGGCATGCCTTCTCCTCATGACGTTCTTGGCCTCCTAGCT 776
633 GACAAAATCCTTGCTGCTTCTCTTCATGGTGCTGTCC CGCCGGA 677
777 CTGCCCCCTCCCTGGGGGGGAGAGATGGGGGGGCTTGGAAAGGAGCA 826
678 GGAGGCCATCCATCCGTCCCTGGGATGCAACATGGG GT 715
827 GGGAGCCTTGGCCTCTCCAAGGGAAAGCCTAGTGGCCTAGACCCCTCCT 876
716 CCCAATGCCTGAGGAGAAGACCCCCCCCCAAGGCTGAcT CGCTTTC 761
877 CCCATGGCTAGAAGTGGGCCTGCACCATACATCTGTGTCCGCCCTCT 926
762 ACCAGGGCCACCAGGGCCATCCAGTGTGcaTAATT 797
927 ACCCCTCCCCCCCACGTAGGGCACTGTAGTGGACCAAGCACGGGACAGC 976

Quality: 183.3 Length: 338
Ratio: 0.554 Gaps: 3
Percent Similarity: 61.846 Percent Identity: 61.846

Mlerk6.Seq x Mc6.Seq 14:13

14:13

5

Quality: 104.9 Length: 411
Ratio: 0.373 Gaps: 1
Percent Similarity: 39.858 Percent Identity: 39.858

Mlerk6.Seq x Lerk5.Seq

14:01

HEK/ELK Meeting Minutes

B. Davison in the absence of Doug Cerretti.

Nicole Nelson summarized the recent screening of a murine embryonic cDNA library with a combination of LERKs(A2,C6) plus GSK beta kinase(Fred Fletcher's probe): Hybridization conditions were 42 C in 50% Stark's followed by washes at 63 C, 0.1X SSC.

13 initial positives were obtained of which 4 did not repeat; Nicole will rescreen these using a less stringent wash protocol. Currently, the sequence analysis indicates that the collection contains at least 1 gsk Beta clone, 1 gsk Beta-like clone and interestingly, a new LERK, LERK-6.

All four cysteine residues are conserved while inspection of the carboxy terminal portion of the sequence indicates that LERK-6 fits into the GPI-linked class(similar to LERKS 1,3 and 4). The amino terminus of the protein is apparently lacking about 20 or 25 amino acid residues in the current clone. In the binding region, the LERK-6 DNA sequence displays about 70% identity with A2(LERK 3) corresponding to 288 bp of overlap.

Efforts are now being directed at identification of a source to obtain the human homologue.

REDACTED

REDACTED

0051



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301) 231-5520 Telex: 898-055 ATCCNORTH • FAX: 301-770-2587

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3 AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Immunex Corporation
Attention: Stephen L. Malaska
Legal Affairs Department
51 University Street
Seattle, WA 98101

Deposited on Behalf of: Immunex Corporation (Docket No. 2826)

Identification Reference by Depositor:

ATCC Designation

Recombinant phage lambda gt10 vector,
clone lambda 13M LERK-6 (murine)

75829

The deposit was accompanied by: a scientific description a proposed taxonomic description indicated above.

The deposit was received
accepted.

by this International Depository Authority and has been

AT YOUR REQUEST:

We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested
viable.

On ~~that~~ date, the culture was

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Bobbie A. Brandon
Bobbie A. Brandon, Head, ATCC Patent Depository

Date: